All News

The new guidance aims to improve supply for harm reduction programs.

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.

Your weekly roundup of the latest news from Drug Topics®.

Erickson shares her tips on managing burnout as a student pharmacist.

The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.

Take a look back at our most popular news from September 2022.

However, researchers found that only a small percentage of plans use available real-world evidence studies and economic evaluations in their coverage policies.

The future of independent pharmacy requires the combination of what makes independent pharmacy special and the digital landscape found elsewhere in retail.

Positive effects emerge when patients get medical care, avoid deadly fentanyl-laced street drugs.

Your weekly roundup of the latest news from Drug Topics®.

The National Commission on Correctional Health Care and 166 other national organizations recently signed a letter to Senate leadership advocating for increased access to buprenorphine.

Hospitalization, disability, having private high-deductible, Medicare Advantage, or no coverage were risk factors associated with medical debt.

ViiV Healthcare reports long-term positive results for its drug, Rukobia (fostemsavir).

The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile.

Your weekly roundup of the latest news from Drug Topics®.

Your weekly roundup of the latest news from Drug Topics®.

Your weekly roundup of the latest news from Drug Topics®.

Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.

This recall of propofol because of particulates seen in vials follows a previous one in July 2022.

Take a look back at our most popular news from August 2022.

Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.

Your weekly roundup of the latest news from Drug Topics®.

Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.

Drug manufacturers are rejecting the program’s blanket discounts involving contract pharmacies. A flurry of litigation has ensued.

Consumers are purchasing dietary supplements that support or boost the immune system like never before.

Opioid use disorder—how can we battle the epidemic of overdoses?

Your weekly roundup of the latest news from Drug Topics®.

Examining the results of a study examining the role of supplements and diets in managing psoriasis.

Overall numbers may be lower, but the obese, racial/ethnic minorities, and those without health care access have higher numbers of undiagnosed diabetes

The rule change could save money for millions.